Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 1
1997 7
1998 23
1999 59
2000 121
2001 172
2002 321
2003 393
2004 489
2005 624
2006 809
2007 986
2008 1184
2009 1316
2010 1473
2011 1619
2012 1779
2013 1859
2014 2048
2015 2101
2016 2049
2017 2153
2018 2110
2019 2114
2020 1660
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

24,173 results
Results by year
Filters applied: . Clear all
Page 1
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.
Salles G, Barrett M, Foà R, Maurer J, O'Brien S, Valente N, Wenger M, Maloney DG. Salles G, et al. Adv Ther. 2017 Oct;34(10):2232-2273. doi: 10.1007/s12325-017-0612-x. Epub 2017 Oct 5. Adv Ther. 2017. PMID: 28983798 Free PMC article. Review.
For all of these diseases, clinical trials have demonstrated that rituximab not only prolongs the time to disease progression but also extends overall survival. ...Using the wealth of data published on rituximab during the last two decades, we review the preclinical …
For all of these diseases, clinical trials have demonstrated that rituximab not only prolongs the time to disease progression but als …
Rituximab: 13 open questions after 20years of clinical use.
Pavanello F, Zucca E, Ghielmini M. Pavanello F, et al. Cancer Treat Rev. 2017 Feb;53:38-46. doi: 10.1016/j.ctrv.2016.11.015. Epub 2016 Dec 22. Cancer Treat Rev. 2017. PMID: 28056413 Review.
Rituximab improved the prognosis of all B-cell derived lymphoproliferative diseases, but despite 20years of intensive use, it remains a drug with a number of still obscure characteristics and unanswered questions. ...Finally, despite of 20years of research, it is still unc
Rituximab improved the prognosis of all B-cell derived lymphoproliferative diseases, but despite 20years of intensive use, it remains
[Rituximab: its efficacy, effectiveness and safety in the treatment of multiple sclerosis].
Midaglia L, Mora L, Mulero P, Sastre-Garriga J, Montalban X. Midaglia L, et al. Rev Neurol. 2018 Jan 1;66(1):25-32. Rev Neurol. 2018. PMID: 29251340 Free article. Review. Spanish.
AIM: To address the main aspects of efficacy, effectiveness and safety of rituximab in the treatment of MS. DEVELOPMENT: PubMed review of placebo-controlled clinical trials, prospective open label studies, retrospective observational studies, and case series using ritux
AIM: To address the main aspects of efficacy, effectiveness and safety of rituximab in the treatment of MS. DEVELOPMENT: PubMed revie …
A tale of two antibodies: obinutuzumab versus rituximab.
Freeman CL, Sehn LH. Freeman CL, et al. Br J Haematol. 2018 Jul;182(1):29-45. doi: 10.1111/bjh.15232. Epub 2018 May 9. Br J Haematol. 2018. PMID: 29741753 Review.
While rituximab has dramatically improved outcomes for patients with CD20(+) malignancies for two decades, responses are not universal and resistance can develop. ...The benefit conferred by obinutuzumab over rituximab may be context-specific and vary based on histo …
While rituximab has dramatically improved outcomes for patients with CD20(+) malignancies for two decades, responses are not universa …
Rituximab biosimilars for lymphoma in Europe.
Jurczak W, Długosz Danecka M, Buske C. Jurczak W, et al. Expert Opin Biol Ther. 2019 Oct;19(10):1045-1056. doi: 10.1080/14712598.2019.1665017. Expert Opin Biol Ther. 2019. PMID: 31512535 Review.
However, as with all biologic medicines, the complex development and manufacturing process for rituximab have meant that the medicine attracts high treatment costs. ...Focusing on biosimilars of rituximab, we examine in detail the evidence for biosimilarity for the …
However, as with all biologic medicines, the complex development and manufacturing process for rituximab have meant that the medicine …
GP2013: A Rituximab Biosimilar.
Blair HA. Blair HA. BioDrugs. 2017 Oct;31(5):465-468. doi: 10.1007/s40259-017-0245-2. BioDrugs. 2017. PMID: 28921160 Review.
GP2013 is the second biosimilar of the reference monoclonal anti-CD20 antibody rituximab to be approved in the EU. It is approved for use in all indications for which reference rituximab is approved, including follicular lymphoma (FL), diffuse large B-cell non-Hodgk …
GP2013 is the second biosimilar of the reference monoclonal anti-CD20 antibody rituximab to be approved in the EU. It is approved for …
Rituximab in ANCA-Associated Vasculitis.
Hassan RI, Gaffo AL. Hassan RI, et al. Curr Rheumatol Rep. 2017 Feb;19(2):6. doi: 10.1007/s11926-017-0632-1. Curr Rheumatol Rep. 2017. PMID: 28155022 Review.
PURPOSE OF REVIEW: The purpose of this review is to describe the efficacy and safety of rituximab (RTX) as a remission induction and maintenance therapy in ANCA-associated vasculitis (AAV). ...Rituximab is a therapeutic option to induce and maintain remission in pat …
PURPOSE OF REVIEW: The purpose of this review is to describe the efficacy and safety of rituximab (RTX) as a remission induction and …
Rituximab in the management of acute lymphoblastic leukemia.
Levato L, Molica S. Levato L, et al. Expert Opin Biol Ther. 2018 Feb;18(2):221-226. doi: 10.1080/14712598.2018.1425389. Epub 2018 Jan 17. Expert Opin Biol Ther. 2018. PMID: 29310477
The anti-CD20 chimeric monoclonal antibody rituximab has revolutionized the treatment of B-cell malignancies, significantly improving patient clinical outcome. ...Expert opinion: Data from clinical trials confirm that rituximab enhances the efficacy of chemotherapy …
The anti-CD20 chimeric monoclonal antibody rituximab has revolutionized the treatment of B-cell malignancies, significantly improving …
Current perspective on rituximab in rheumatic diseases.
Schioppo T, Ingegnoli F. Schioppo T, et al. Drug Des Devel Ther. 2017 Oct 3;11:2891-2904. doi: 10.2147/DDDT.S139248. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 29042750 Free PMC article. Review.
Among the wide spectrum of available biological treatments, rituximab (RTX), first used in the treatment of non-Hodgkin's lymphoma, was later approved for rheumatoid arthritis and anti-neutrophil cytoplasmic antibodies-associated vasculitis. Nowadays, in rheumatolog …
Among the wide spectrum of available biological treatments, rituximab (RTX), first used in the treatment of non-Hodgkin's lymp …
Anti-CD20 Blocker Rituximab in Kidney Transplantation.
Sood P, Hariharan S. Sood P, et al. Transplantation. 2018 Jan;102(1):44-58. doi: 10.1097/TP.0000000000001849. Transplantation. 2018. PMID: 28614191 Review.
Rituximab, in combination with IVIg/plasmapheresis, appears to decrease antibody level and increase the odds of transplantation in sensitized recipients. The role of Rituximab in ABOi transplant remains unclear, as similar outcomes are achieved without its use. R
Rituximab, in combination with IVIg/plasmapheresis, appears to decrease antibody level and increase the odds of transplantation in se
24,173 results
Jump to page
Feedback